Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.43 |
| ▸ | MAOB | P27338 | 5/20 | 0.42 |
| ▸ | MAOA | P21397 | 3/20 | 0.41 |
| ▸ | DRD2 | P14416 | 3/20 | 0.41 |
| ▸ | DRD4 | P21917 | 2/20 | 0.41 |
| ▸ | DRD3 | P35462 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10632075 | 0.81 | MEN1 (0.65) | MEN1KMT2APDE3BPDE3AMAOB | |
| SCHEMBL11026437 | 0.81 | MAOB (0.58) | MEN1KMT2APDE3BPDE3AMAOB | |
| SCHEMBL7138979 | 0.76 | KMT2A (0.68) | MEN1KMT2A | |
| SCHEMBL29676340 | 0.76 | KMT2A (0.68) | MEN1KMT2A | |
| SCHEMBL11685320 | 0.75 | MEN1 (0.50) | MEN1KMT2AMAOBMAOADRD2 | |
| SCHEMBL435141 | 0.74 | MEN1 (0.70) | MEN1KMT2A | |
| SCHEMBL7271469 | 0.73 | KMT2A (1.00) | MEN1KMT2A | |
| SCHEMBL14114321 | 0.73 | MEN1 (0.68) | MEN1KMT2APDE3BPDE3A | |
| SCHEMBL2850811 | 0.73 | MEN1 (0.68) | MEN1KMT2A | |
| SCHEMBL14610310 | 0.73 | MEN1 (0.68) | MEN1KMT2APDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120189547-A1 | [18F] LABELLED ANALOGUES OF FLUMAZENIL AS IN VIVO IMAGING AGENTS | GE HEALTHCARE LIMITED (GB) | 2012-07-26 | — | — | US | disclosed |
| US-20120189547-A1 | [18F] LABELLED ANALOGUES OF FLUMAZENIL AS IN VIVO IMAGING AGENTS | GE HEALTHCARE LIMITED (GB) | 2012-07-26 | — | — | US | disclosed |
| US-20120189547-A1 | [18F] LABELLED ANALOGUES OF FLUMAZENIL AS IN VIVO IMAGING AGENTS | GE HEALTHCARE LIMITED (GB) | 2012-07-26 | — | — | US | disclosed |
| WO-2011042550-A1 | [18 F] - LABELLED ANALOGUES OF FLUMAZENIL AS IN VIVO IMAGING AGENTS | GE HEALTHCARE LIMITED (GB) | 2011-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120189547-A1 | [18F] LABELLED ANALOGUES OF FLUMAZENIL AS IN VIVO IMAGING AGENTS | GABRA5, GABRA4, GABRA2 | MEN1 1698/4885KMT2A 1274/4885PDE3B 1163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.